Tumour stem cells and drug resistance (original) (raw)

• Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
  Article CAS PubMed Google Scholar
• Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43–47 (2004).
  Article CAS PubMed Google Scholar
• Morrison, S. J., Wandycz, A. M., Hemmati, H. D., Wright, D. E. & Weissman, I. L. Identification of a lineage of multipotent hematopoietic progenitors. Development 124, 1929–1939 (1997).
  Article CAS PubMed Google Scholar
• Dontu, G., Al-Hajj, M., Abdallah, W. M., Clarke, M. F. & Wicha, M. S. Stem cells in normal breast development and breast cancer. Cell Prolif. 36 (Suppl. 1), 59–72 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Kordon, E. C. & Smith, G. H. An entire functional mammary gland may comprise the progeny from a single cell. Development 125, 1921–1930 (1998).
  Article CAS PubMed Google Scholar
• Price, J. E. & Tarin, D. Low incidence of tumourigenicity in agarose colonies from spontaneous murine mammary tumours. Differentiation 41, 202–207 (1989).
  Article CAS PubMed Google Scholar
• Gioanni, J. et al. In vitro clonogenicity in relation to kinetic and clinicopathological features of breast cancer. Bull. Cancer 75, 285–290 (1988).
  CAS PubMed Google Scholar
• Southam, C. M. & Brunschwig, A. Quantitative studies of autotransplantation of human cancer. Cancer 14, 971–978 (1960).
  Article Google Scholar
• Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994). Original report demonstrating the existence of stem cells in leukaemia.
  Article CAS PubMed Google Scholar
• Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730–737 (1997).
  Article CAS PubMed Google Scholar
• Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738–43 (2004).
  Article CAS Google Scholar
• Dick, J. E. Breast cancer stem cells revealed. Proc. Natl Acad. Sci. USA 100, 3547–3549 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Jamieson, C. H. et al. Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004).
  Article CAS PubMed Google Scholar
• Andrews, P. W. From teratocarcinomas to embryonic stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 405–417 (2002).
  Article PubMed PubMed Central Google Scholar
• Damjanov, I. Teratocarcinoma stem cells. Cancer Surv. 9, 303–319 (1990).
  CAS PubMed Google Scholar
• Sell, S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51, 1–28 (2004).
  Article PubMed Google Scholar
• Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72, 3585–3589 (1975).
  Article CAS PubMed PubMed Central Google Scholar
• Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003). Demonstrates a population of cells in breast cancers possessing markers in common with normal breast stem cells. Small numbers of these cancer stem cells could generate tumours in mice, whereas the non-cancer stem cells could not.
  Article CAS PubMed PubMed Central Google Scholar
• Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA 101, 4158–4163 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
  Article CAS PubMed Google Scholar
• Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178–15183 (2003). Describes the isolation of tumour stem cells from paediatric brain cancers.
  Article CAS PubMed PubMed Central Google Scholar
• Singh, S. K., Clarke, I. D., Hide, T. & Dirks, P. B. Cancer stem cells in nervous system tumors. Oncogene 23, 7267–7273 (2004).
  Article CAS PubMed Google Scholar
• Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003).
  CAS PubMed Google Scholar
• Richardson, G. D. et al. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117, 3539–3545 (2004).
  Article CAS PubMed Google Scholar
• Yu, S., Zhang, J. Z., Zhao, C. L., Zhang, H. Y. & Xu, Q. Isolation and characterization of the CD133+ precursors from the ventricular zone of human fetal brain by magnetic affinity cell sorting. Biotechnol. Lett. 26, 1131–1136 (2004).
  Article CAS PubMed Google Scholar
• Wu, X. et al. Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells. Am. J. Physiol. Heart Circ. Physiol. 287, H480–H487 (2004).
  Article CAS PubMed Google Scholar
• Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029–3035 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Blanpain, C., Lowry, W. E., Geoghegan, A., Polak, L. & Fuchs, E. Self-Renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 118, 635–648 (2004).
  Article CAS PubMed Google Scholar
• Scharenberg, C. W., Harkey, M. A. & Torok-Storb, B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507–512 (2002).
  Article CAS PubMed Google Scholar
• Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2, 48–58 (2002).
  Article CAS Google Scholar
• Kim, M. et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin. Cancer Res. 8, 22–28 (2002).
  CAS PubMed Google Scholar
• Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. & Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337–5339 (1998).
  CAS PubMed Google Scholar
• Miyake, K. et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8–13 (1999).
  CAS PubMed Google Scholar
• Doyle, L. A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665–15670 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Dean, M., Rzhetsky, A. & Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156–1166 (2001).
  Article CAS PubMed Google Scholar
• Schinkel, A. H. et al. Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491–502 (1994).
  Article CAS PubMed Google Scholar
• Zhou, S., Zong, Y., Lu, T. & Sorrentino, B. P. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques 35, 1248–1252 (2003).
  Article CAS PubMed Google Scholar
• Zhou, S. et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl Acad. Sci. USA 99, 12339–12344 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Jonker, J. W. et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl Acad. Sci. USA 99, 15649–15654 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797–1806 (1996).
  Article CAS PubMed Google Scholar
• Summer, R. et al. Side population cells and Bcrp1 expression in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L97–L104 (2003).
  Article CAS PubMed Google Scholar
• Alvi, A. J. et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5, R1–R8 (2003).
  Article PubMed Google Scholar
• Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 7, 1028–1034 (2001). Shows that ABCG2 is highly expressed in normal stem cells and is responsible for the low retention of fluorescent dyes used to identify the SP population.
  Article CAS PubMed Google Scholar
• Lassalle, B. et al. 'Side Population' cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells. Development 131, 479–487 (2004).
  Article CAS PubMed Google Scholar
• Asakura, A. & Rudnicki, M. A. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp. Hematol. 30, 1339–1345 (2002).
  Article PubMed Google Scholar
• Martin, C. M. et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev. Biol. 265, 262–275 (2004).
  Article CAS PubMed Google Scholar
• Lechner, A., Leech, C. A., Abraham, E. J., Nolan, A. L. & Habener, J. F. Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem. Biophys. Res. Commun. 293, 670–674 (2002).
  Article CAS PubMed Google Scholar
• Terunuma, A., Jackson, K. L., Kapoor, V., Telford, W. G. & Vogel, J. C. Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. J. Invest. Dermatol. 121, 1095–1103 (2003).
  Article CAS PubMed Google Scholar
• Hirschmann-Jax, C. et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101, 14228–14233 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Kondo, T., Setoguchi, T. & Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl Acad. Sci. USA 101, 781–786 (2004). Shows that long-established cancer cell lines contain a small population of SP cells that behave as cancer stem cells. Like cancer stem cells isolated from brain tumours, these SP cells can give rise to the multiple differentiated cell types found in the cell line.
  Article CAS PubMed PubMed Central Google Scholar
• Mizoguchi, T. et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J. Natl Cancer Inst. 82, 1679–1683 (1990).
  Article CAS PubMed Google Scholar
• Nishiyama, K. et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 71, 3611–3619 (1993).
  Article CAS PubMed Google Scholar
• Bates, S. E. et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol. Cell. Biol. 9, 4337–4344 (1989).
  CAS PubMed PubMed Central Google Scholar
• Mickley, L. A. et al. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem. 264, 18031–18040 (1989).
  Article CAS PubMed Google Scholar
• Knutsen, T. et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/ P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosom. Cancer 23, 44–54 (1998).
  Article CAS PubMed Google Scholar
• Mickley, L. A., Spengler, B. A., Knutsen, T. A., Biedler, J. L. & Fojo, T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J. Clin. Invest. 99, 1947–1957 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Sato, N., Leopold, P. L. & Crystal, R. G. Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia. J. Natl Cancer Inst. 93, 1858–1864 (2001).
  Article CAS PubMed Google Scholar
• Cotsarelis, G. & Millar, S. E. Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7, 293–301 (2001).
  Article CAS PubMed Google Scholar
• Houghton, P. J. et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64, 2333–2337 (2004).
  Article CAS PubMed Google Scholar
• Ozvegy-Laczka, C. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65, 1485–1495 (2004).
  Article PubMed Google Scholar
• Burger, H. et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940–2942 (2004).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002).
  Article CAS PubMed Google Scholar
• Hofmann, W. K. et al. Presence of the BCR–ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102, 659–661 (2003).
  Article CAS PubMed Google Scholar
• Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).
  CAS PubMed Google Scholar
• Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
  Article CAS PubMed Google Scholar
• Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792–3800 (2002).
  Article CAS PubMed Google Scholar
• Paterson, S. C., Smith, K. D., Holyoake, T. L. & Jorgensen, H. G. Is there a cloud in the silver lining for imatinib? Br. J. Cancer 88, 983–987 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• La Rosee, P., Shen, L., Stoffregen, E. P., Deininger, M. & Druker, B. J. No correlation between the proliferative status of Bcr–Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol. J. 4, 413–419 (2003).
  Article CAS PubMed Google Scholar
• Agrawal, M. et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650–656 (2003).
  CAS PubMed Google Scholar
• Bakker, M. et al. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. AntiCancer Res. 19, 2349–2353 (1999).
  CAS PubMed Google Scholar
• Bates, S. E. et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin. Cancer Res. 10, 4724–4733 (2004).
  Article CAS PubMed Google Scholar
• Peck, R. A. et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 19, 3130–3141 (2001).
  Article CAS PubMed Google Scholar
• Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W. & Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60, 47–50 (2000).
  CAS PubMed Google Scholar
• Allen, J. D. et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1, 417–425 (2002).
  CAS PubMed Google Scholar
• Cisternino, S., Mercier, C., Bourasset, F., Roux, F. & Scherrmann, J. M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood–brain barrier. Cancer Res. 64, 3296–3301 (2004).
  Article CAS PubMed Google Scholar
• Weisenthal, L. M. & Lippman, M. E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat. Rep. 69, 615–632 (1985).
  CAS PubMed Google Scholar
• Secchi, G. C. Cancer chemotherapy. Ann. Ital. Med. Int. 5, 288–295 (1990).
  CAS PubMed Google Scholar
• Dean, M. Towards a unified model of tumor suppression: lessons learned from the human patched gene. Biochimica et Biophysica Acta 1332, M43–M52 (1997).
  CAS PubMed Google Scholar
• Nusslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795–801 (1980).
  Article CAS PubMed Google Scholar
• Hahn, H. et al. A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental anomalies. J. Biol. Chem. 271, 12125–12128 (1996).
  Article CAS PubMed Google Scholar
• Hahn, H. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841–851 (1996). Positional cloning of PTCH as the tumour-suppressor gene responsible for the nevoid basal-cell carcinoma syndrome. Established a role for the HH–PTCH pathway in cancer.
  Article CAS PubMed Google Scholar
• Johnson, R. L. et al. Human homolog of patched, a candidate gene for the Basal Cell Nevus Syndrome. Science 272, 1668–1671 (1996).
  Article CAS PubMed Google Scholar
• Berman, D. M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559–1561 (2002).
  Article CAS PubMed Google Scholar
• Berman, D. M. et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846–851 (2003).
  Article CAS PubMed Google Scholar
• Watkins, D. N. et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422, 313–317 (2003).
  Article CAS PubMed Google Scholar
• Thayer, S. P. et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851–856 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Karhadkar, S. S. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707–712 (2004).
  Article CAS PubMed Google Scholar
• Dalton, W. S. et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75, 815–820 (1995).
  Article CAS PubMed Google Scholar
• Belpomme, D. et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol. 11, 1471–1476 (2000).
  Article CAS PubMed Google Scholar
• Millward, M. J. et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Cancer 67, 1031–1035 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Milroy, R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br. J. Cancer 68, 813–818 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Wishart, G. C. et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol. 12, 1771–1777 (1994).
  Article CAS PubMed Google Scholar
• Sonneveld, P. et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br. J. Haematol. 115, 895–902 (2001).
  Article CAS PubMed Google Scholar
• List, A. F. et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98, 3212–3220 (2001).
  Article CAS PubMed Google Scholar
• Greenberg, P. L. et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J. Clin. Oncol. 22, 1078–1086 (2004).
  Article CAS PubMed Google Scholar
• Baer, M. R. et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100, 1224–1232 (2002).
  Article CAS PubMed Google Scholar
• Rago, R. P. et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol. 51, 297–305 (2003).
  Article CAS PubMed Google Scholar
• Seiden, M. V. et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol. 86, 302–310 (2002).
  Article CAS PubMed Google Scholar
• Toppmeyer, D. et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 8, 670–678 (2002).
  CAS PubMed Google Scholar
• Bramwell, V. H. et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin. Cancer Res. 8, 383–393 (2002).
  CAS PubMed Google Scholar
• Sparreboom, A. et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10, 719–728 (1999).
  Article CAS PubMed Google Scholar
• van Zuylen, L. et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. 6, 1365–1371 (2000).
  CAS PubMed Google Scholar
• Sandler, A. et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res. 10, 3265–3272 (2004).
  Article CAS PubMed Google Scholar
• Guns, E. S., Denyssevych, T., Dixon, R., Bally, M. B. & Mayer, L. Drug interaction studies between paclitaxel (Taxol) and OC144-093 — a new modulator of MDR in cancer chemotherapy. Eur. J. Drug Metab. Pharmacokinet. 27, 119–126 (2002).
  Article CAS PubMed Google Scholar
• Oldham, R. K., Barnett, D. & Ramos, Z. A phase II study of paclitaxel/CBT–1, an MDR modulator. Proc. Am. Soc. Clin. Oncol. 22, 148 (2003).
  Google Scholar